arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

ARDELYX, INC.

ARDX
$3.48 ▼ -0.15 (-4.13%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
56 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
25
Health
Poor
Bearish
auto_awesome

Analytical Summary

ARDELYX, INC. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $863.3M
Dividend Yield —
Revenue Growth 23.8% ↘
Op. Margin -10.3% ↗
ROIC -3.1% ↗
FCF / Share $-0.03 ↗
Trailing P/E —
Price / Book 5.8x
FCF Yield —
Debt / Equity 1.69
info Valuation on last close. End-of-day price, Sep 23, 2026.

56-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$120.88M
↑ +23.8% —
Net Income Profit after all expenses
$-16.72M
↑ +12.4% —
Operating Margin Operating profit as % of sales
-10.3%
↑ +70.4% 15th
FCF / Share Free cash flow per share
$-0.03
↑ +80.3% —
Long-Term Debt Long-term obligations
$251.82M
↑ +23.7% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
13
Returns ↑
20
Financial Health ↑
32
Cash Quality ↓
49

bar_chart Data from SEC EDGAR XBRL filings

Synced 2 days ago 15 years · 56 quarters